Table 1 Patient characteristics (n = 96, data from medical records)

From: Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation

Age at transplantation, mean ± SD (years) 17.7 ± 9.5 (range 0.3–30.0)
Age at eye examination, mean ± SD (years) 34.4 ± 11.1 (range 16.9–54.2)
Time from transplantation to eye examination, mean ± SD (years) 16.8 ± 4.9 (range 6.0–26.1)
Recipient gender n (%)
Male 44 (46)
Female 52 (54)
Donor gender n (%)
Male 49 (51)
Female 46 (48)
Missing data 1 (1)
Recipient/donor gender mismatch n (%)
Female recipient/ male donor 23 (24)
Male recipient/ female donor 18 (19)
Donor type n (%)
Sibling 59 (62)
Other related 7 (7)
Unrelated donor 30 (32)
Diagnosis n (%)
Acute myeloid leukemia 32 (33)
Acute lymphoblastic leukemia 10 (10)
Other malignancies (CML/ MDS/ NHL) 29 (30)
Benign haematological diseases (anaemia/ thalassaemia) 17 (18)
Immunodeficiency/ metabolic disease 8 (8)
Conditioning regime n (%)
Chemotherapy Bu/Cy 73 (76)
Chemotherapy and antithymocyte globulin 21 (22)
None 2 (2)
GVHD prophylaxis n (%)
None 1 (1)
CyA 7 (7)
CyA + Mtx 86 (90)
CyA + MMF/ Sirolimus/ Tacrolimus/ Mtx/ Other 2 (2)
History of radiotherapy affecting eye area (incl. CNS radiotherapy) 4 (4)
  1. Bu busulfan, Cy cyclophosphamide, CyA cyclosporine, CML chronic myeloid leukemia, MDS myelodysplastic syndrome, MMF mycophenolate mofetil, Mtx methotrexate, NHL non-Hodgkin’s lymphoma